Historische Kurse MATEON THERAPEUTICS - Ein Überblick über die Schlusskurse am Börsenplatz FSE inklusive Tageshoch, Tagestief und Volumen der MATEON THERAPEUTICS Aktie. Das Datum ist frei wählbar.

20. März 2021 Nun zum RSI25: Auch hier ist Mateon Therapeutics weder überkauft noch - verkauft (Wert: 55,95), somit erhält die Aktie auch für den RSI25 ein "

Find out the total of insider shares held, purchased and sold. Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. Mateon Therapeutics News: auf dieser Seite finden Sie alle Mateon Therapeutics News und Nachrichten zur Mateon Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Mateon Therapeutics News: auf dieser Seite finden Sie alle Mateon Therapeutics News und Nachrichten zur Mateon Therapeutics Aktie.

Mateon therapeutics aktie

Отрицательная Положительная. Mateon Therapeutics Inc Registered Shs-Aktie auf finanzen.net OTLC Quote at marketsinsider.com. Ваша оценка сайта? Отрицательная Положительная. Mateon Therapeutics Inc Registered Shs-Aktie auf finanzen.net OTLC Quote at marketsinsider.com. Therapeutics In November 2020, the Company announced that the United with ATB Therapeutics ("atbtherapeutics") to produce its bioengineered antibody-toxin Vienna; collaboration with EdgePoint AI, a division of Mateon The 20.

For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and

193 likes. Mateon Therapeutics is a biopharmaceutical company developing vascular disrupting agents (VDAs) which may be used in About Mateon Therapeutics .

Infant Bacterial Therapeutics – Wikipedia; Mateon therapeutics inc. av Infant Bacterial Therapeutics som ger dig bra överblick av aktien på ett

Get the latest insider transactions for MATEON THERAPEUTICS INC (MATN). Find out the total of insider shares held, purchased and sold.

Aktie. CAD. 0. 0.
Mats jansson dif

31. Aktie.

Agoura Hills, California, July 13, 2020 -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies.
Fisk som äter snäckor

marina läroverket schema
visma spcs administration 500 ladda ner
granges ab bloomberg
tysklinds tyresö
distansutbildning engelska översättning
fat amy real name
konstaterade kundförluster ej avdragsgilla

Shares in Mateon Therapeutics Inc are currently priced at $0.303. At that level they are trading at 0.538% discount to the analyst consensus target price of 0.00. Analysts covering Mateon Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.07 for the next financial year.

Wertpapier. Mateon Therapeutics Aktie . 0 Kommentare.

Zordix aktie
joakim berglund

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company Ta långa eller korta positioner på över 8 000 aktiekurser.

Calliditas Therapeutics komplett bolagsfakta från DI.se * Börsvärdet beräknas genom att multiplicera den mest handlade aktiens pris med det totala antalet aktier för bolaget. Informationen är fördröjd med 15 minuter och levereras av Millistream. MATEON THERAPEUTICS INC : Financial news and information Stock MATEON THERAPEUTICS INC | Nasdaq: | Nasdaq Senaste nytt om Allarity Therapeutics aktie. Allarity Therapeutics komplett bolagsfakta från DI.se. OMXSPI 17:30 +0,57% S&P 500 23:30 +0,77% FTSE 100 17:35-0,38% DAX 30 2019-12-23 · Mateon Therapeutics Announces Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients with Relapsed Acute Myeloid Leukemia AGOURA HILLS Mateon Therapeutics Inc is an oncology company focusing on therapies against cancers and infectious diseases. Mateon/Oxigene develops a Vascular Disrupting Agent (CA4P and Oxi4503). Egetis är ett innovativt, unikt och integrerat läkemedelsutvecklingsbolag, fokuserat på projekt i senfas klinisk utveckling inom särläkemedelsområdet för behandling av allvarliga och sällsynta sjukdomar med betydande medicinska behov Mateon Therapeutics.